In the Claims:

- 1. (currently amended) A method for treating unstable or overactive urinary bladder in a mammal, said method comprising orally administering to a mammal a pharmaceutically effective dose of an antimuscarinic agent and when needed, whereby a symptomatic relief of urgency and/or frequency is achieved.
- 2. (currently amended) The method as claimed in claim 1, wherein the antimuscarinic agent is one or more compounds selected from tolterodine, and related compounds a racemate to tolterodine, the corresponding (S)-enantiomer to tolterodine, the 5-hydroxymethyl metabolite of said (S)-enantiomer to tolterodine, festoterodine, or a pharmaceutically acceptable salt of said racemate, (S)-enantiomer, 5-hydroxymethyl metabolite of said (S)-enantiomer to tolterodine, or fesoterodine.
- 3. (previously presented) The method according to claim 2, wherein the compound is tolterodine or a pharmaceutically acceptable salt thereof.

4. (canceled)

- 5. (currently amended) The method according to $\frac{1}{2}$ of claims claim 1 to 4, wherein the mammal is human.
- 6. (previously presented) The method according to claim 5, wherein the pharmaceutically effective dose is 2 mg or 4 mg of the antimuscarinic agent, administered as a controlled release tablet or capsule.

- 7. (previously presented) The method according to claim 5, wherein two pharmaceutically effective doses of the antimuscarinic agent are administered daily at an interval of 8-12 hours.
- 8. (previously presented) The method according to claim 7, wherein the pharmaceutically effective dose is 1 mg of the antimuscarinic agent, administered as an immediate release tablet or capsule.
- 9. (previously presented) The method according to claim 7, wherein the pharmaceutically effective dose is 1 mg or 2 mg of the antimuscarinic agent, administered as a controlled release tablet or capsule.
- 10. (currently amended) The method according to claim 1 any of claims 1-5 or 7-9, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 8 hours.
- 11. (currently amended) The method according to $\underline{\text{claim 1}}$ any of claims 1-5 or 7-9, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 9 hours.
- 12. (currently amended) The method according to claim 1 any of claims 1-5 or 7-9, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 10 hours.

- 13. (currently amended) The method according to $\frac{1}{2}$ any of claims 1-5 or 7-9, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 11 hours.
- 14. (currently amended) The method according to $\underline{\text{claim 1}}$ any of claims 1-5 or 7-9, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 12 hours.
 - 15. (canceled)